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ABSTRACT 
Characterization of Calmodulin 
From Cg Astrocytoma Cells and Rat Cerebrum 
Jay A1an Gates 
1986 
Calmodulin (CaM) regulates many processes associated with cellular 
proliferation and CaM antagonists can inhibit cell growth. To determine whether 
or not exploitable pharmacological differences exist between a normal and 
malignant tissue, we purified CaM by preparative polyacrylamide gel 
electrophoresis (PAGE) from rat cerebrum and the Cg malignant astrocytoma cell 
line and compared the biochemical and pharmacological properties of the two 
preparations. The concentration of biologically active CaM in the heated, 
acidified supernatants was similar, being 37 + 14 ng/mg protein in cerebrum 
compared to 26 + 7 ng/mg protein in Cg cells. The proteins eluted similarly 
from a preparative PAGE column, co-migrated in denaturing SDS-PAGE gels, and 
showed similar shifts of mobility when calcium was present during 
electrophoresis. 
We tested the sensitivity of the two preparations of CaM to several classes 
of antagonists. No significant difference in the sensitivities to any of the 
classes of drugs was demonstrable when assayed by the inhibition of a CaM- 
sensitive cyclic nucleotide phosphodiesterase. We conclude that at least in 
one malignant cell line, the pharmacological properties of CaM are similar to 
those of normal tissue. 
I 

1 
INTRODUCTION 
Calmodulin and normal cellular proliferation 
Calmodulin (CaM*) is a heat and acid-stable, low molecular weight protein 
which was first described independently by Cheung (1) and Kakiuchi (2) as an 
activator of cyclic AMP phosphodiesterase. Teo and Wang showed that the same 
protein, in a purified form, bound calcium at multiple sites; they suggested 
that it was the complex of activator protein and calcium which was responsible 
for increased cyclic AMP phosphodiesterase activity (3). CaM, as the major 
intracellular calciuim receptor, has since been shown to be involved in many 
processes that are necessary for normal cellular proliferation (for reviews 
see 4-7). For example, CaM changes in concentration as cells enter and traverse 
the cell cycle. Chafouleas et al demonstrated that CaM levels are elevated 
two-fold at late and/or early S phases during the growth cycle of CHO-K^ 
cells (8). Sasaki and Hidaka showed that CaM concentrations increased after 
CH0-K;[ cells entered the S phase and reached a maximum level at the late G£ 
or early M phase (9). It has been shown by MacManus and coworkers that fol lowing 
partial hepatectomy, CaM increases in regenerating hepatocytes, an increase 
which coincides with the time when calcium is required for the initiation of 
DNA synthesis (10). CaM is also known to stimulate the polymerization and 
depolymerization of microtubules. Welsh et al used indirect immunofluorescence 
techniques to demonstrate the localization of CaM to the spindle of mitotic 
*The abbreviations used are: CaM, calmodulin; EGTA, ethylene glycol bis (13- 
aminoethyl ether)-N,N,N',N'-tetraacetic acid; FBS, fetal bovine serum; PMSF, 
phenylmethylsulfonylf1uoride; TEMED, N,N,N1,N'-tetramethylethylenediamine; 
PAGE,polyacrylamide gel electrophoresis; PDE, phosphodiesterase; SDS, sodium 
dodecylsulfate. W-7, N-(6-aminohexyl)-5-chloro-l-napthalenesulfonamide 
. 
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cells (11). Marcum and coworkers expanded on Welsh's work and showed that 
during anaphase CaM was restricted to the chromosome-to-pole region of the 
mitotic apparatus and that CaM was involved in the control of calcium dependent 
inhibition and reversal of microtubule assembly jjn vitro (12). Welsh et al 
also showed that while both CaM and tubulin are components of the mitotic 
apparatus, their localizations throughout mitosis are distinctly different and 
specific (13). Job and coworkers showed that a subpopulation of microtubules 
was almost totally resistant to the effect of calcium or CaM alone but 
disassembled rapidly in the presence of both at apparently physiological 
concentrations (14). It is also known that CaM modulates enzymes necessary 
for generation of cellular energy. Anderson and Cormier showed that CaM from 
the pea plant, Pi sum satavum c., modulates NAD kinase activity in a calcium- 
dependent fashion (15). CaM also modulates enzymes necessary for control of 
cyclic nucleotide metabolism (1,16). Uzunov and Weiss demonstrated that of 
the several molecular forms of cyclic adenosine 3',5'-monophosphate 
phosphodiesterase, only one was really susceptible to activation by CaM (17). 
It has also been shown that CaM is capable of stimulating adenylate cyclase 
activity (18,19). 
Calmodulin in states of abnormal cellular proliferation 
In states of abnormal cellular proliferation, as occurs in transformed 
or malignant cells, control of calcium and CaM mediated events is altered (for 
reviews see 7,20-22). Watterson and coworkers found that CaM comprised 
approximately 1.3% of the soluble protein in homogenates of chicken embryo 
fibroblasts infected and transformed by Rous sarcoma virus as compared to 0.3% 
of the soluble protein in homogenates of normal fibroblasts (23). Balk et al 
have observed that transformed chick embryo fibroblasts have the ability to 
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grow in calcium concentrations that are 10-fold lower than that required for 
proliferation of normal cells (24). Chafouleas and coworkers used 
radioimmunoassay techniques to demonstrate a two-fold increase in the 
intracellular concentration of CaM in mammalian tissue culture cells 
transformed by oncogenic viruses (25). By comparing fast-growing Morris 
hepatoma tissue lines to normal adult liver tissue, Criss and Kakiuchi 
demonstrated that both CaM activity and total calcium are increased in the 
neoplastic tissue (20). Wei et al have demonstrated, in slowly and rapidly 
growing hepatomas, that increased CaM levels are directly proportional to tumor 
growth rate (26). It should be noted that Veigl and coworkers believe that 
the variation in CaM content, observed between normal and transformed cells, 
is complex and may in part depend on culture conditions; they suggest that the 
apparent inability of transformed cells to down-regulate CaM levels is a 
function of differing abilities of normal and transformed cultures to respond 
to cell-to-cell contact and/or transmediated cellular regulation signals (27). 
The inhibition of abnormal cellular proliferation by CaM antagonists 
Drugs that share the property of CaM antagonism are known to inhibit the 
growth of many malignant cell lines (for review see 7). For example. Speaker 
et al used the macrophage-like cell line J774 (established from a murine 
reticulum cell sarcoma) to demonstrate the inhibition of growth and Fc-mediated 
phagocytosis by the CaM antagonist trif1uoperazine (28). In several studies 
Hait and coworkers have shown that the CaM antagonists calmidazoliurn, melittin, 
pimozide, trifluoperazine, and chlorpromazine inhibit the growth and/or 
clonogenicity of human and murine leukemic cells, and rat astrocytoma cells; 
they have demonstrated that the potency of these drugs, as inhibitors of cell 
growth, correlates directly with their activity as inhibitors of CaM (29-32). 
Ito and Hidaka were able to demonstrate a significant anti-tumor effect when 

they gave intraperitoneal injections of W-7, a calmodulin antagonist, to mice 
implanted with solid Sarcoma-180 (33). Wei et al, using a soft agar clonogenic 
assay, showed that trif1uoperazine and W-7 inhibited colony formation in the 
human breast cancer cell line, MDA-MB-231 (34). MacNeil and coworkers concluded 
that W-7 and prochlorperazine markedly inhibited DNA synthesis in B-16 melenoma 
cells, and that the inhibitory effect of these CaM antagonists was reversed 
by the presence of exogenous CaM (35). 
CaM antagonists have also been shown to, at least partially, overcome 
tumor cell resistance to certain chemotherapeutic agents. For example, Tsuruo 
et al have shown that certain CaM inhibitors, as well as calcium antagonists, 
enhance the cytotoxic effects of vincristine and adriamycin in resistant P388 
leukemic cells; this effect was attributed to enhanced intracellular levels 
of vincristine and adriamycin, possibly due to inhibition of their outward 
transport (36). In a similar system, Ganapathi and Grabowski demonstrated 
that trifluoperazine markedly enhanced cellular retention of, and sensitivity 
to, adriamycin only in adriamycin-resistant tumor sublines and not in 
adriamycin-sensitive lines (37). 
The existence of novel calmodulins 
Recently, novel CaMs have been identified in several organisms including 
Tetrahymena (38), Dictyosteliurn (39), and trypanosomes (40). These altered 
forms of the molecule differ structurally, functionally, and antigenically 
(41) from mammalian CaM. For example, Yazawa and coworkers have described a 
Tetrahymena CaM (differing from bovine brain CaM by 11 amino acid substitutions 
and one deletion) which is unique in its ability to activate Tetrahymena 
guanylate cyclase (38). Ruben et al have isolated CaM from the trypanosome 
parasite which is structurally and functionally distinct from that of host 
tissue (40). Marshak and coworkers demonstrated that Dictyosteliurn CaM was 
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able to activate bovine brain cyclic nucleotide PDE as effectively as bovine 
brain CaM; however, it could activate pea NAD kinase 5 times greater than 
bovine brain CaM (39). One of the key distinctions between Dictyostelium CaM 
and bovine brain CaM is that Dictyostel i um CaM's lysine 115 is not trimethyl ated 
and has been shown by Gregori et al to be a ubiquitin conjugation site (42); 
these investigators have demonstrated that mammalian CaM, which contains 
trimethylysine at the 115 position, does not form conjugates with ubiquitin 
and thus, unlike dictyostelium CaM, is "protected" from ubiquitin-dependent, 
protein degradation pathways. 
Furthermore, recent evidence suggests that different CaMs might exist 
within the same organism. Putkey and coworkers have isolated a distinct "CaM- 
like" gene from chicken which results in a protein product similar to normal 
chicken CaM, yet it contains 16 amino acid substitutions and activates rat 
brain PDE with slightly different kinetics (43). Siegel and Wright report the 
isolation of a "CaM-isotype" from beef testes which activates cyclic nucleotide 
PDE equally as well as does "standard" beef testes CaM, yet which stimulates 
a distinctly different protein methylation pattern in rat liver cytosolic 
fractions (44). 
The potential use of calmodulin antagonists as antineoplastic agents 
Based on the above findings, and the remarkable genetic diversity of tumor 
cells, we postulated that alterations in CaM during malignant transformation 
could occur which might help explain the ability of tumor cells to thrive in 
lower concentration of calcium compared to their normal counterparts (45) or 
which might provide a target for selective inhibition by drugs (7). Because 
of the mounting interest in the potential use of CaM antagonists as 
antineoplastic agents alone (7,29-34), or to modulate resistance to known 
chemotherapeutic agents (36,37), it would be important to know whether 
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exploitable pharmacological differences exist between the molecule from a 
malignant cell and that of its normal counterpart. 
Isolation of CaM by preparative polyacrylamide gel electrophoresis 
We also tested the feasibility of preparing CaM by preparative-PAGE, a 
simple, rapid technique for the isolation and purification of other proteins 
(17). Therefore, we have established conditions for purifying CaM from normal 
and malignant cells by preparative-PAGE and report the application of these 
methods to the C5 astrocytoma cell line and normal cerebrum. 

7 
MATERIALS AND METHODS 
Cell culturing techniques 
Cg rat astrocytoma cells were obtained from the American Type Culture 
Collection (Rockville, MD). This glial cell tumor of rats was originally 
induced by intravenous injection of N-nitrosomethylurea. Cells were cultured 
at 37°C in a 5% atmosphere of CO2 in plastic flasks in monolayers in Dulbecco's 
modification of Eagle's medium supplemented with 10% FBS. Cells were passed 
twice weekly and were shown to be free of contamination by routinely assaying 
for mycoplasm, bacteria and fungi. 
Isolation and Purification of CaM from C^ astrocytoma cells and rat cerebrum 
Cg astrocytoma cells, at a concentration of approximately 100,000 cells 
per ml, were seeded on to 250 x 250 x 20 mm, plastic plates (Nunc Corp., 
Denmark) and were incubated at 37°C in Dulbecco's modification of Eagle's 
medium with 10% FBS in a 5% atmosphere of CO2 for 3-4 days until confluent 
(doubling time approximately 18 hrs). Cells were harvested with a rubber 
spatula, pooled, and centrifuged at 450 x g for 20 minutes at 2°C. Medium was 
discarded and cells were washed with cold, fresh medium. Cells were homogenized 
in 1.5 volumes of phosphate buffer containing 90 mM Na^PO^ 20 mM Na2HP04, 
0.1 mM EGTA, 0.5 mM PMSF, (pH 6.0) for twenty seconds with a Tissumizer^ 
(Tekmar, Cincinnati, OH). The homogenate was then sonicated 10 pulses at 50 
watts, (TekmarR, Cincinnati, OH) in the presence of additional PMSF (0.5 mM). 
All procedures were carried out on ice. 
Female Sprague-Dawley rats (Charles River, Kingston) were maintained on 
normal rat chow and distilled water. Rats weighing approximately 200 grams 
were decapitated with a Harvard Dispatcher. The cerebrum was removed, weighed, 
rinsed with distilled water, and patted dry. Tissue was suspended in 1.5 

8 
volumes of the phosphate buffer (pH 6.0) and was homogenized and sonicated as 
above. 
The sonicated material was then placed in a boiling water bath for five 
minutes. The coagulated proteins were removed by centrifugation at 3400 x g 
for 20 minutes at 2°C (Model J-6B centrifuge, Beckman, Palo Alto, CA). The 
supernatant was readjusted to a pH of 6.0, placed in a boiling water bath for 
five minutes then recentrifuged. A portion of the supernatant was dialyzed 
overnight (against 50 mM Tris, 0.2 mM CaCl2, pH 7.4) for determination of CaM 
activity and concentration of protein. The remaining supernatant was 
concentrated by ultrafiltration (YM5 membrane, mol. wt. cut off of 5,000, 
Amicon, Danvers, MA). Sucrose was added to the concentrate to yield a final 
concentration of 0.32M and was applied to a 345 mm x 25 mm gel filtration 
column (G-75 Super Fine Sephadex, Pharmacia, Piscattaway, NJ) pre-equi1ibrated 
with el ution buffer containing 5mM TRIS-base, 0.1 mM EGTA, 1 mM mercaptoethanol, 
(pH 7.4). 1.5 ml fractions were collected overnight at 2°C and the first 70 
fractions were assayed for calmodulin activity the fol lowing morning. Fractions 
containing calmodulin activity were pooled and concentrated by ultrafiltration 
(Amicon, YM5). 
Calmodulin was further purified by a preparative PAGE. A 10% gel column 
(Shandon Southern Instruments, Inc., Sewickley, PA) was prepared with a gel 
buffer containing 39 mM NaH2P04, 123 mM Na2HP04, 0.46% TEMED, and 1 mM EGTA 
(pH 7.0); electrolyte buffer contained 88 mM NaH2P04, 23 mM Na2HP04, 640 mM 
glycine, and 1 mM EGTA (pH 6.0). Partially purified CaM (1.5 ml of Cg astrocytoma 
or rat cerebrum post-Sephadex concentrate) containing 0.32 M sucrose was appl ied 
to the gel. Electrophoresis was started at 25 mA for the first hour and 
maintained at 60 mA thereafter, using a constant current power supply (Bio- 
Rad Laboratories, Model 500/200, Richmond, CA). Protein was eluted with 100 
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mM TRIS buffer containing 0.1 mM calcium (pH 7.6) at a flow rate of 0.3 
ml/minute. The entire procedure was carried out in a cold-room and the column 
was continuously cooled by passing refrigerated coolant through an outer sleeve 
and an inner finger. Each fraction was collected for twenty minutes, diluted 
1:10, and assayed for CaM activity. Fractions containing CaM activity were 
pooled and concentrated by ultra-filtration (Amicon YM-5). Aliquots of 
concentrated material were stored at -70°C without loss of activity for up to 
6 months. 
Assay of CaM and effects of CaM antagonists 
The activity of calmodulin was determined by its ability to activate a 
CaM-sensitive form of cyclic nucleotide phosphodiesterase which was prepared 
from mouse cerebrum as previously described (17). The activity of cyclic AMP 
phosphodiesterase was determined by the 1 uciferin-1uciferase method (46). The 
assay mixture contained 50 mM glycylglycine buffer myokinase (0.25 unit), 
pyruvate kinase (0.50 unit), 25 mM ammonium acetate, 3 mM MgC12» 0.1 mM CaCl2, 
0.4 mM cyclic AMP, 5 mM dithiothreitol, 0.26 mM phosphoenolpyruvate, 1 nM ATP 
(pH 8.0) and phosphodiesterase in a total volume of 100 microliters. 
Concentrations of phosphodiesterase and time of incubation were chosen to 
insure linearity of the assay. Using our preparations of phosphodiesterase 
and CaM, there was at least a 4 fold activation of the enzyme in all experiments. 
Quantitation of biologically active CaM in each sample was determined by 
comparing its activation of phosphodiesterase to the activation of 
phosphodiesterase by known quantities of a purified preparation of CaM from 
bovine brain (Calbiochem, LaJolla, CA). 
In these experiments, three to five concentrations of each tissue sample 
were assayed for CaM activity to determine the range in which the activity was 
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1 inear with respect to concentration of tissue. Comparisons between the tissues 
were carried out on the same day using freshly prepared tissue in the same assay. 
The effect of antagonists on CaM-dependent activity of phosphodiesterase 
was measured by the ability of various concentrations of drug to inhibit the 
activation of phosphodiesterase in the presence of 2 units of CaM. One unit 
of activity was defined as the amount of calmodulin required to achieve 50% 
of the maximum activation of the enzyme. The effects of CaM antagonists and 
their vehicles on the standard curve were determined and corrected as necessary. 
Comparisons between the tissues were done in the same assay. 
Analytical Electrophoresis 
SDS PAGE was performed as described by Laemmli (47). A 16% acrylamide 
gel (pH 8.9) was used with sample buffers containing 0.11 M Tris, 0.11 M 
sucrose, 0.2% SDS and either 5 mM EGTA or 5 mM calcium chloride (pH 7.5). 
Electrolyte buffer contained 0.43 M glycine, 0.05 M TRIS, 0.1% SDS (pH 8.7). 
Proteins were visualized by the use of Coomassie staining. Molecular weight 
standards were obtained from Pharmacia (Piscataway, NJ). 
Protein determinations and statistical analysis 
Protein concentrations were determined by the method of Lowry (48) and 
statistical significance by Student's t-test. 
Drugs 
Trifluoperazine and chlorpromazine were gifts from Dr. Alfred Brown (Smith 
Kline Beckman, Philadelphia, PA): Fluphenazine was a gift from Dr. Fred 
Gorelick; Flunarazine, Melittin and the histones, H^ and H2B were purchased 
from Sigma Co. (St. Louis, M0): calmi dazol i urn was kindly provided by Dr. James 
Long, Janssen Pharmaceutical Company (Piscattaway, NJ). Calmidazoliurn was 
dissolved in dimethylsulfoxide; the effect of this vehicle was determined for 
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and subtracted from all parts of the assay. All other drugs were dissolved 
in distilled water. 
Miscel1aneous 
PMSF, 5' adenosine-monophosphate, cyclic AMP, and firefly luciferin- 
luciferase were obtained from Sigma Co. (St. Louis, MO); myokinase and pyruvate 
kinase were obtained from Boehringer-Mannheim (New York, NY); bovine brain 
calmodulin was obtained from Calbiochem (LaJolla, CA); Spectrapor^ dialysis 
tubing with a m.w. cutoff of 3,500 was obtained from Spectrum Medical Ind., 
Inc. (Los Angeles, CA) and was prepared by boiling in double-distilled water. 
The remaining reagents were electrophoretic or reagent grade and were purchased 
from commercial sources. 
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RESULTS 
Concentration of biologically active CaM from astrocytoma cells and cerebrum 
The concentration of biologically active CaM in the supernatant fraction 
was similar in C5 astrocytoma cells (26 + 7 ng/mg protein, n = 3) to that of 
cerebrum (37 + 14 ng/mg protein, n = 4) (p > 0.5). 
Purification of CaM from Cfi astrocytoma and cerebrum 
CaM from the acid-heat treated supernatant was further purified by gel 
filtration and preparative PAGE. Both preparations eluted identically from 
the gel filtration column (data not shown). This material was pooled and 
concentrated to 1.5 ml then applied to the preparative PAGE apparatus. Figure 
1 shows the electrophoretic profiles of CaM emerging from the preparative PAGE. 
CaM from both tissues eluted in a single major peak of activity after 4 hours 
of electrophoresis in fractions 10 to 30. The material from each source was 
found to be homogeneous under denaturing conditions (Figure 2). 
Table 1 shows the results of purification of CaM. Following acid and 
heat precipitation, there was similar CaM present in C5 astrocytoma cells and 
rat cerebrum. Gel filtration resulted in a 2 fold purification of the molecule 
from both sources but more importantly reduced the concentration of 
contaminating nucleotides which otherwise interfere with the luciferin- 
luciferase assay. Following preparative PAGE of the concentrated material, 
the recovery of CaM varied between experiments but was in the range of 40%- 
70%. Overall, in several experiments, the recovery of CaM from cerebrum was 
greater than the recovery from the C5 cells. 
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Characterization of CaM from Cfi astrocytoma and cerebrum 
The preparations of purified CaM were further character!'zed according to 
their ability to migrate in polyacrylamide gels under denaturing conditions. 
Figure 2 demonstrates that the electrophoretic mobility of the CaM prepared 
from C5 astrocytoma cells was similar to that prepared from rat cerebrum and 
had an apparent m.w. of 15,000. Both migrated identically to CaM from bovine 
brain purchased from a commercial source. Figure 2 also shows that all 
preparations of CaM showed similar shifts in electrophoretic mobility in the 
presence of calcium. 
Effect of CaM antagonists on CaM purified from C^ astrocytoma cells and rat 
cerebrum 
Table 3 shows that the effect of CaM antagonists on CaM purified from C5 
astrocytoma cells and CaM purified from rat cerebrum was simi 1 ar. Calmidazol i urn 
and melittin, were the most potent compounds studied (IC50 values of 10-14 nM 
and 12-15 nM respectively). The basic peptides, histone H]_ and histone H2B 
were slightly less potent (IC50 of 22-36 nM). Flunarazine, a piperazine 
derivative was more potent than the phenothiazines (IC50 3 pM). Fluphenazine 
and trifluoperazine were intermediate in potency (IC50 5-8 pM and 9 pM 
respectfully) and chiorpromazine was the least potent inhibitor studied (IC50 
of 16-20 pM). 
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DISCUSSION 
These studies demonstrate the feasibility of purifying CaM by preparative 
PAGE and also demonstrate the similarities between CaM purified from rat 
cerebrum and a malignant astrocytoma cell line. The concentration of 
biologically active CaM was not significantly different in the two preparations. 
This observation confirms earlier work by Brostrom and Wolff (49) who found 
similar concentrations and similar biochemical characteristics of CaM in C5 
cells compared to that of brain. However, others have found that the 
concentration of CaM was increased in certain tumors and transformed cell lines 
(reviewed in 7,22). Since cerebrum contains many cell types which conceivably 
vary in their concentration of CaM (50), while the C5 line is a malignancy of 
astrocytes, purified preparations of astrocytes might be necessary to 
demonstrate significant differences in concentrations of CaM. 
The CaM isolated from cerebrum and C5 astrocytoma cells were also 
qualitatively similar. For example, they had the same estimated m.w. by gel 
filtration (data not shown) and by SDS-PAGE (Figure 2); they showed identical 
shifts of mobility in the presence of calcium (Figure 2) and; they had similar 
sensitivity to inhibition by antagonists (Table 2). 
We studied several different types of CaM antagonists to optimize the 
chances of demonstrating pharmacological differences between the CaMs. For 
example, the phenothiazines require calcium-dependent hydrophobic, geometric 
and ionic interactions with CaM (51) while the histones may be more dependent 
on the ionic properties of the molecules (52). Flunarazine may be a tissue 
selective inhibitor of CaM-stimulated phosphodiesterase (53). However, as 
shown in Table 2, we found no significant differences in the sensitivity of 
the preparations of CaM to any of the antagonists. The similar pharmacological 
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properties of the two CaM's is further evidence for their structural 
equivalence. 
Recently, oncomodulin, a unique calcium-binding protein resembling (3- 
parvalbumin has been found exclusively in tumor cells and human placenta (54). 
We have not identified this protein in our preparations. This can be explained 
by the recently observed phenomena that unlike CaM, oncomodulin is a far more 
potent activator of CaM-sensitive phosphodiesterase from heart than of 
phosphodiesterase from brain (55,56) and might go undetected in our assay. 
This study also demonstrated that preparative PAGE is a rapid and simple 
technique for purifying CaM. This procedure was based on earlier work on the 
purification of cyclic nucleotide phosphodiesterase by Uzunov and Weiss (17). 
These investigators demonstrated the separation of CaM from phosphodiesterase 
using preparative PAGE, but were unable to separate the CaM from other proteins. 
To overcome this, we used a higher percentage acrylamide gel (10% vs 7.5%) and 
a lower pH buffer system to slow the migration of other proteins out of 
proportion to the smaller, more acidic CaM molecule. This resulted in excellent 
separation of CaM from contaminating proteins (Table 2 and Figure 2). Although 
the final products appear homogenous on SDS PAGE, the use of two dimensional 
electrophoresis and isoelectric focusing or high pressure liquid chromatography 
might prove helpful in determining ultimate purity. The entire procedure takes 
less than 48 hours including the initial gel filtration step which removed the 
high concentration of nucleotides present in the malignant cells which 
interfere with the 1 uciferin-1uciferase assay. Since many investigators assay 
CaM by other techniques, it is likely that direct preparative PAGE of the acid- 
heat treated soluble supernatant would give excellent results that could be 
completed in one day. 
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The 70% yield and approximately 20 fold purification from the already 
partially purified soluble supernatant is comparable to standard methodology 
(57-59). The overall yield was in the range of 20 mg of CaM per kg of original 
tissue. 
CaM purified by this technique was authenticated by; 1) its identical 
migration to that of bovine brain CaM in SDS gels (Figure 2); 2) its 
characteristic shift in electrophoretic mobility in the presence of calcium 
(Figure 2); 3) its ability to activate phosphodiesterase and; 4) its inhibition 
by CaM antagonists (Table 2). 
The recovery of CaM from Cg cells compared to that from cerebrum was 
generally lower after preparative-PAGE. It seems uni ikely that the differences 
were due to contaminating proteases because of the presence of excess 
concentration of the protease inhibitors PMSF and EGTA. It is also possible 
that the CaM of tumor cells remained tightly associated with a CaM-binding 
protein and migrated differently during electrophoresis. Flowever, the presence 
of the calcium-chelator, EGTA, during all steps of the purification should 
have allowed for separation of CaM from most of its binding sites. 
The pharmacological properties of CaM from a normal and malignant cell 
line have not been previously compared. The similarities demonstrated in the 
present studies may have further implications. For example, others have shown 
that hydrophobic, cationic molecules can inhibit the growth of malignant cells 
in vitro (7,21,29-32,34) and in vivo (33) and have correlated this effect with 
the potency of the agents as CaM antagonists (30). Furthermore, CaM antagonists 
were shown to enhance the cytotoxicity of bleomycin (60,61) and modulate the 
resistance of certain cells to adriamycin and vincristine (36,37). These 
results have led to the inclusion of phenothiazines in clinical cancer 
chemotherapeutic trials (62). However, the inability to demonstrate 
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pharmacological differences between CaM from a normal tissue and a malignant 
cell line raises questions regarding potential selectivity of drug action. 
This does not rule out the possibility that alterations of CaM exist in other 
malignant tissues, or that selectivity could be achieved through variations 
in uptake or distribution of the drug. The use of preparative PAGE should 
provide a simple technique for comparing the molecule from other normal and 
malignant cell lines to determine if exploitable differences might exist. 
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LEGENDS TO TABLES 
TABLE 1 Purification of CaM from C5 Astrocytoma and rat cerebrum 
CaM was prepared from C6 astrocytoma cells and rat cerebrum 
as described in Methods. Fractions under a single peak 
of CaM activity (isolated by gel filtration or preparative 
PAGE) were obtained, pooled, concentrated, and assayed as 
described in methods. 
TABLE 2. Effect of Antagonists on the Activity of CaM from C5 
Astrocytoma Cells and Rat Cerebrum 
CaM and phosphodiesterase were purified as described in 
Methods. The effect of antagonists and their vehicles was 
determined in the presence of 2U of CaM. The range of 
concentration of drugs was; trif1uoperazine 1-128 pM, 
fluphenazine 3-100 pM, chlorpromazine 6-100 pM, 
calmidazol i urn 0.001-0.2 pM, melittin 0.001-0.5 pM, histone 
HI 0.01-1 pM, histone H2 0.01-1 pM, and flunarazine 1-100 
pM. IC50 was defined as the concentration of agent 
necessary to inhibit the activation of phosphodiesterase 
by 50%. Each IC50 value was determined from individual 
dose-response curves run in triplicate. There was less 
than a 5% inhibition of phosphodiesterase by drugs when 
CaM was omitted from the assay. 
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TABLE 2 
Effect of Antagonists on CaM Purified from Cg and 
rat cerebrum 
DRUGS C6 
Phenothiazines 
Trif1uoperazine 8.6 
FIuphenazine 5.0 
Chlorpromazine 16.0 
Peptides 
Melittin 0.01 
Hi Histone 0.02 
H2B Histone 0.05 
Other 
Calmidazoliurn 0.01 
FIunarazine 2.5 
Rat Cerebrum 
iCgn (mM) 
9.2 
8.5 
20.0 
0.02 
0.03 
0.04 
0.01 
3.3 
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Figure 1. 
Figure 2. 
LEGENDS TO FIGURES 
Preparative polyacrylamide gel electrophoresis of CaM from C5 
astrocytoma cel Is and rat cerebrum. 1-2 mg of protein was appl ied 
to the 10% polyacrylamide gel column and collected as described 
in methods. Broken line indicates the activity of 
phosphodiesterase in the absence of added CaM. 
SDS-polyacrylamide gel electrophoresis of CaM purified from C5 
astrocytoma cells, rat cerebrum, and bovine brain. CaM was 
purified from C5 astrocytoma and rat cerebrum by preparative 
PAGE as described in Methods. 5 pg of protein was applied to 
each lane of the 16% gel in a buffer containing either 5 mM EGTA 
(-) or 5 mM CaC12 ( + ). Molecular weight standards included 
ribonuclease A (13,700), chymotripsinogen A (25,000), ovalbumin 
(43,000), and bovine serum albumin (67,000). 
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